In a report released yesterday, Joanne Wuensch from Citi maintained a Buy rating on Boston Scientific, with a price target of $125.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joanne Wuensch’s rating is based on Boston Scientific’s promising growth prospects and strategic initiatives. The company has demonstrated a strong ability to exceed market expectations, with a focus on high-growth end markets and innovative product rollouts. Their management has consistently delivered organic growth rates above 10%, which outpaces the market’s compound annual growth rate. Additionally, Boston Scientific has shown consistent expansion in adjusted operating margins and robust free cash flow conversion, which are key indicators of financial health.
Moreover, the company’s strategic focus on innovation and diversification, supported by a disciplined capital allocation strategy, further strengthens its position. This includes significant investments in research and development, numerous active clinical trials, and a history of successful mergers and acquisitions. The company’s commitment to growing in markets such as Neuromodulation, Urology, and Endoscopy, along with the anticipated growth in the PFA market, underscores its potential for sustained success. These factors collectively contribute to Wuensch’s Buy rating for Boston Scientific.
Wuensch covers the Healthcare sector, focusing on stocks such as Medtronic, Tandem Diabetes Care, and Abbott Laboratories. According to TipRanks, Wuensch has an average return of 6.0% and a 60.82% success rate on recommended stocks.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $132.00 price target.